VIVEbiotech forecasts significant growth in lentiviral vectors and CAR-T therapies for 2024

Natalia spoke about her projections on lentiviral vectors and CAR-T therapies.

Lentiviral vectors have a high efficiency in inducing long-lasting immunity. They are one of the most widely used viral vectors for establishing CAR-T cells. In the resulting piece of a two-part series, Natalia recalls how CAR-T therapies are expected to grow at a rate of 19% in 2024. Natalia anticipates their applications to expand beyond oncology including solid tumors, to in-vivo treatments, and non-oncological areas like autoimmune diseases or vaccines.

You can read this first part here: https://www.pharmamanufacturing.com/home/article/33035530/2024-pharma-predictions-therapeutic-advances-manufacturing-tech